STERIS plc (NYSE:STE) Shares Purchased by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its holdings in shares of STERIS plc (NYSE:STE) by 40.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 255,925 shares of the medical equipment provider’s stock after acquiring an additional 73,829 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned about 0.26% of STERIS worth $56,186,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Russell Investments Group Ltd. raised its position in shares of STERIS by 8.3% during the 1st quarter. Russell Investments Group Ltd. now owns 58,841 shares of the medical equipment provider’s stock worth $13,235,000 after purchasing an additional 4,494 shares during the last quarter. State Board of Administration of Florida Retirement System raised its holdings in shares of STERIS by 3.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 106,346 shares of the medical equipment provider’s stock worth $23,909,000 after acquiring an additional 3,342 shares during the last quarter. Caden Capital Partners LP lifted its position in shares of STERIS by 80.0% in the fourth quarter. Caden Capital Partners LP now owns 82,312 shares of the medical equipment provider’s stock valued at $18,096,000 after acquiring an additional 36,576 shares in the last quarter. Diversify Advisory Services LLC purchased a new stake in shares of STERIS in the first quarter valued at $903,000. Finally, Perpetual Ltd boosted its stake in shares of STERIS by 9.3% during the first quarter. Perpetual Ltd now owns 40,571 shares of the medical equipment provider’s stock valued at $9,121,000 after acquiring an additional 3,437 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Analysts Set New Price Targets

STE has been the subject of a number of analyst reports. StockNews.com raised shares of STERIS from a “hold” rating to a “buy” rating in a research report on Tuesday, August 13th. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a report on Thursday, August 8th. KeyCorp raised their price objective on STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a report on Tuesday, September 3rd. Stephens reaffirmed an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a research report on Wednesday, August 7th. Finally, JMP Securities reiterated a “market outperform” rating and set a $265.00 target price on shares of STERIS in a research report on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, STERIS presently has a consensus rating of “Moderate Buy” and an average price target of $246.00.

Insider Transactions at STERIS

In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the transaction, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at $10,603,710. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the sale, the chief financial officer now owns 42,930 shares in the company, valued at $10,603,710. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Christopher S. Holland sold 473 shares of the firm’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $239.68, for a total value of $113,368.64. Following the sale, the director now owns 582 shares in the company, valued at $139,493.76. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

STERIS Price Performance

Shares of STERIS stock opened at $239.38 on Tuesday. The business’s fifty day moving average price is $236.63 and its 200 day moving average price is $225.55. STERIS plc has a twelve month low of $195.47 and a twelve month high of $248.24. The company has a current ratio of 2.33, a quick ratio of 1.49 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $23.66 billion, a P/E ratio of 62.66 and a beta of 0.83.

STERIS (NYSE:STE) last released its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping analysts’ consensus estimates of $1.98 by $0.16. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The company had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.27 billion. During the same period last year, the business posted $2.00 EPS. The company’s quarterly revenue was down .4% compared to the same quarter last year. As a group, research analysts anticipate that STERIS plc will post 9.05 earnings per share for the current year.

STERIS Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 20th. Shareholders of record on Thursday, September 5th were paid a dividend of $0.57 per share. This is an increase from STERIS’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a yield of 0.95%. The ex-dividend date of this dividend was Thursday, September 5th. STERIS’s payout ratio is currently 59.69%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.